These results suggest that gefitinib has an inhibitory effect on the expression of phosphorylated EGFR and MAPK ERK1/2 that can regulate proliferation and TGF-β-mediated EMT in NSCLC cells. This evidence concerns the gene MAPK3 and non-small cell lung carcinoma.